Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial, Novo Nordisk said in a release.The headline results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback